2019 Fiscal Year Research-status Report
Studying and targeting a proto-oncogenic Internal Ribosome Entry Site (IRES) in p53 mRNA that is activated by the most frequent mutations in cancer
| Project/Area Number |
18K07229
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | P53 mRNA / mRNA translation / IRES / Cancer mutation / P53 isoform / Delta160p53 |
|---|
| Outline of Annual Research Achievements |
We had already completed tasks 1 and 2. We have now completed the colony formation assays as well as the xenograft studies. We had to stop experiments for almost 2 months due to the COVID19 pandemic but are still on time. Our last challenge will be to try to screen for a drug that can inhibit the IRES and inactivate D160p53.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
Task 1 was concluded last year
Task 2 was concluded last year
Task 3 has now been concluded (colony formation assays and tumorigenesis assay in the xenograft model showing that IRESd160 and D160p53 are tumorigenic)
Task 4 is under way. This is the last one (drug screening to identify a small compound that might inhibit d160 expression)
|
| Strategy for Future Research Activity |
Everything is going on time, even if we had to stop research for 2 months due to COVID19 (and we are still now mostly stopped), I still think we should be able to conclude the project on time. Our future plan is to try to identify a small drug that inhibits D160p53 expression and might be used for cancer therapy
|
| Causes of Carryover |
We used a less money than expected, but we'll probably need it this year to finalize the project.
|
